Navigation Links
N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
Date:3/13/2013

BOULDER, Colo., March 13, 2013 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma") a leader in the development of therapeutics that target S-nitrosoglutathione reductase (GSNOR), announced today that it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis (CF).  The study is a multicenter, double-blind, randomized, placebo-controlled evaluation of ascending doses of N6022 in patients who have two copies of the F508del-CFTR mutation, the most common and serious form of CF.

The clinical study announced today is being conducted in collaboration with the Cystic Fibrosis Foundation's Therapeutics Development Network (TDN), and the lead principal investigator for the study is Scott Donaldson , M.D., at The University of North Carolina, Chapel Hill.  The first patient was dosed this week at National Jewish Health in Denver.  The primary objective of the study is to evaluate the safety of repeat doses of N6022.  Secondary and exploratory objectives include the evaluation of N6022 serum levels, lung function, and other markers of disease activity in CF.

"We are indebted to the cystic fibrosis clinicians and nurses who have given us such valuable advice, to the members of the TDN who have been instrumental in getting this first trial started, and to the patients who will be volunteering for participation. With this first trial, we look forward to paving the way to a new class of therapy for cystic fibrosis," said Charles Scoggin , M.D., President and Chief Executive Officer of N30 Pharma.

About Cystic FibrosisCystic fibrosis is the most common, life-threatening, genetic disease of Caucasians, affecting approximately 30,000 people in the United States and 70,000 people worldwide.  Approximately 48% of the total CF patient population, in the U
'/>"/>

SOURCE N30 Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... States will increase to a value of ... driven by expansion in the large direct energy device ... be increasingly adopted due to the advantages they offer ... key findings from Decision Resources Group,s coverage of the ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
(Date:12/19/2014)... 2014 An evening dress is perfect for ... closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled its new ... in this great shopping platform. Customers can view ... hard work, Discount-Dress.com has been accepted and praised by customers ... easier shopping stage for clients. In order to expand its ...
(Date:12/19/2014)... (HealthDay News) -- New research warns parents that buying an older ... Nearly half of teen drivers killed in the United States ... 11 years old and often lacked important safety features that are ... teen drivers killed in crashes were in cars at least six ... old, 31 percent were in cars 11 to 15 years old, ...
(Date:12/19/2014)... -- Potentially illness-causing E. coli bacteria were found on ... to a new study. Researchers checked cilantro, basil ... markets in Los Angeles and Orange counties in California, ... samples tested, 24 percent were positive for E. coli. ... researchers. Both types of bacteria can cause sometimes ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... pass,companion bill and send measure to President, ALBANY, ... of the Protecting the Medicaid Safety Net Act of,2008, ... The bill,prevents massive increases in costs for people in ... "Today,s vote is a victory for all New York ...
... antibiotics sufficient to treat eye disease, study finds ... communities with moderate levels of the eye disease trachoma, ... with the antibiotic azithromycin may be sufficient to eliminate ... at the London School of Hygiene & Tropical Medicine,s ...
... needed to prove that oversulfated chondroitin sulphate caused deaths, ... researchers say they,ve confirmed that lots of the blood ... a man-made chemical called oversulfated chondroitin sulfate. , ... Biotechnology . , And, according to a paper published ...
... at the Congressional Gold Medal ceremony in the Capitol ... Below are the,Speaker,s remarks:, "Good morning. It is ... the House and Senate to honor Dr. Michael DeBakey. ... Representative Al,Green, and others who worked with them for ...
... 75-cent Per Pack Increase Would Help Raise $390 ... Ohio leaders should,fund a proposed economic stimulus plan ... prevention funds, recommends a report released,today by the ... this tobacco tax alternative would reduce smoking, save ...
... Corporation,(NYSE: STE ) today announced that its Board ... amount of $0.06 per common share. The,dividend is payable ... close of,business on May 14, 2008., About STERIS, ... a healthier today and,safer tomorrow through knowledgeable people and ...
Cached Medicine News:Health News:AARP Thanks New York's Representatives for Supporting Bill to Protect People in Medicaid 2Health News:Annual Trachoma Treatments May Be Unnecessary 2Health News:Researchers Identify Contaminant in Tainted Heparin 2Health News:Researchers Identify Contaminant in Tainted Heparin 3Health News:Pelosi: 'By Literally Fixing Broken Hearts, Dr. DeBakey Has Given Hope and Health to Millions' 2Health News:New Report: Increasing Ohio's Tobacco Tax Would Fund Economic Stimulus Plan and Preserve Highly-Successful Tobacco Prevention Program 2Health News:New Report: Increasing Ohio's Tobacco Tax Would Fund Economic Stimulus Plan and Preserve Highly-Successful Tobacco Prevention Program 3Health News:New Report: Increasing Ohio's Tobacco Tax Would Fund Economic Stimulus Plan and Preserve Highly-Successful Tobacco Prevention Program 4Health News:STERIS Corporation Declares Regular Quarterly Dividend 2Health News:STERIS Corporation Declares Regular Quarterly Dividend 3
... Triad Plus PVP-I Prep Gel ... PVP-I Prep Gel is film forming, ... action that has been known to ... gram-positive bacteria (including antibiotic resistant), fungi, ...
... HIBICLENS bonds with ... a protective, germ-killing field. ... fast acting antimicrobial effect, ... irritation potential promotes compliance ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
Medicine Products: